New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - estradiol hemihydrate 0.62mg equivalent to oestradiol 50 µg/24 hours;  ; norethisterone acetate 2.7mg equivalent to norethisterone acetate 140 µg/24 hours;   - transdermal patch - 50/140 - active: estradiol hemihydrate 0.62mg equivalent to oestradiol 50 µg/24 hours   norethisterone acetate 2.7mg equivalent to norethisterone acetate 140 µg/24 hours   excipient: acrylic adhesive dipropylene glycol oleic acid povidone silicone adhesive - treatment of symptoms of oestrogen deficiency in postmenopausal women with an intact uterus. prevention of osteoporosis in postmenopausal women with an intact uterus.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - estradiol 4.33mg equivalent to 50 µg/24h oestradiol; estradiol hemihydrate 0.62mg equivalent to oestradiol 50 µg/24 hours;  ; norethisterone acetate 2.7mg equivalent to norethisterone acetate 140 µg/24 hours;   - transdermal patch - 50 + 50/140 - active: estradiol 4.33mg equivalent to 50 µg/24h oestradiol excipient: 1,3-butylene glycol acrylic adhesive bentonite dipropylene glycol ethylenevinylacetate copolymer lecithin liquid paraffin oleic acid polyisobutylene synthetic adhesive active: estradiol hemihydrate 0.62mg equivalent to oestradiol 50 µg/24 hours   norethisterone acetate 2.7mg equivalent to norethisterone acetate 140 µg/24 hours   excipient: acrylic adhesive dipropylene glycol oleic acid povidone silicone adhesive

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - estradiol hemihydrate - transdermal patch - 50 microgram(s)/24 hours - natural and semisynthetic estrogens, plain; estradiol

Ireland - English - HPRA (Health Products Regulatory Authority)

theramex ireland limited - estradiol hemihydrate - transdermal patch - 50 microgram(s)/24 hours - natural and semisynthetic estrogens, plain; estradiol

Ireland - English - HPRA (Health Products Regulatory Authority)

theramex ireland limited - estradiol hemihydrate; norethisterone acetate - transdermal patch - 50 microg/24h +170 microgram(s)/24 hours - natural and semisynthetic estrogens, plain; estradiol, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - estradiol hemihydrate; norethisterone acetate - transdermal patch - 50 microg/24h +170 microgram(s)/24 hours - natural and semisynthetic estrogens, plain; estradiol, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - estradiol - transdermal patch - 100 microgram(s)/24 hours - natural and semisynthetic estrogens, plain; estradiol

Ireland - English - HPRA (Health Products Regulatory Authority)

rottapharm ltd - estradiol - transdermal patch - 75 microgram(s)/24 hours - natural and semisynthetic estrogens, plain; estradiol

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg); norethisterone acetate, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hyprolose; purified talc; magnesium stearate; hypromellose; triacetin - short term symptomatic treatment of postmenopausal oestrogen deficiency (see dosage and administration and clinical trials). for the prevention of postmenopausal bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of kliogest should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. see precautions and dosage and administration. kliogest is for use in postmenopausal women with an intact uterus. in perimenopausal women treated with kliogest the incidence of vaginal bleeding is unacceptably high and therefore therapy should not be initiated sooner than one year after the last menstrual period.

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - estradiol; norethisterone acetate - transdermal patch - norethisterone and estrogen